TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.00E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 3.50E+3nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 3.80E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: 1.40E+4nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair
TargetGenome polyprotein [2420-3010](Hepatitis C virus genotype 1b (isolate Con1) (HCV))
Merck Sharp & Dohme
US Patent
Merck Sharp & Dohme
US Patent
Affinity DataEC50: >1.00E+5nMT: 2°CAssay Description:To measure cell-based anti-HCV activity of selected compounds of the present invention, replicon cells were seeded at 5000 cells/well in 96-well coll...More data for this Ligand-Target Pair